“The existing scenario has exposed some structural weaknesses inside the EU’s medicines source chain in addition to a significant dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides reported. She advised that provide chain concerns be resolved within an EU pharmaceutical strategy envisioned to generally be releas